As a rival to CRISPR in the gene-editing field, zinc finger nuclease technology is making a name for itself. LSIPR hears from Sandy Macrae, CEO of Sangamo Therapeutics, one of the key players in this area.
While CRISPR gene-editing and the battle over its patents continue to dominate headlines, a lesser known contender is making a name for itself, partly thanks to the drive of one company.
“Without a doubt, zinc finger nuclease (ZFN) editing is superior to CRISPR editing,” claims Sandy Macrae, president and CEO of Sangamo Therapeutics based in Richmond, California.
Sangamo’s proprietary technology is based on a naturally-occurring class of proteins called zinc finger DNA-binding proteins (ZFPs), which recognise and bind to specific sequences of DNA. A nuclease, which is a functional domain that cuts DNA, is attached to the ZFP portion to make a ZFN.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sangamo Therapeutics, Sandy Macrae, ZFN, zinc finger nuclease technology, CRISPR, gene-editing, genetics, Kite, Gilead